TYRUKO

This brand name is authorized in Austria, Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, United Kingdom

Active ingredients

The drug TYRUKO contains one active pharmaceutical ingredient (API):

1 Natalizumab UNII 3JB47N2Q2P - NATALIZUMAB

Natalizumab is a selective adhesion-molecule inhibitor and binds to the α4-subunit of human integrins, which is highly expressed on the surface of all leukocytes, with the exception of neutrophils. Read about Natalizumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TYRUKO Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AG03	Natalizumab	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AG Monoclonal antibodies
Discover more medicines within L04AG03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3047734
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1231745001
Country: FR	Base de données publique des médicaments	Identifier(s): 60779570
Country: IT	Agenzia del Farmaco	Identifier(s): 050762018
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1097837